CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report-Reference-Cited by-同舟云学术

CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report

Published:2023-05 Issue:5 Volume:18 Page:650-656
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kim Dong-Wan,Kim Sang-We,Camidge D. Ross,Shu Catherine A.,Marrone Kristen A.,Le Xiuning,Blakely Collin M.,Park Keunchil,Chang Gee-Chen,Patel Sandip Pravin,Kar Gozde,Cooper Zachary A.,Samadani Ramin,Pluta Michael,Kumar Rakesh,Ramalingam Suresh

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis;Lee;J Thorac Oncol,2017

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

4. Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target;Le;J Thorac Oncol,2021

5. Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC;Tu;JCI Insight,2022

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Adenosinergic Pathway in Non-Small Cell Lung Cancer;Cancers;2024-09-13

2. Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis;ESMO Open;2024-09

3. Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73;Journal of Medicinal Chemistry;2024-05-29

4. HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer;Lung Cancer;2024-03

5. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine;Nature Reviews Clinical Oncology;2024-02-29